{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T12:10:09Z","timestamp":1756555809721,"version":"3.44.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,30]]},"DOI":"10.7759\/cureus.91281","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T11:32:54Z","timestamp":1756553574000},"source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Papillary Thyroid Carcinoma: A Retrospective Biomarker Study"],"prefix":"10.7759","author":[{"given":"Dimitra","family":"Spyroulia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Lefantzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyros","family":"Lygeros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirini","family":"Nikolaou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stylianos","family":"Triantos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Theodosiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassilis","family":"Samaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavlos","family":"Maragkoudakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26115173","article-title":"Thyroid cancer: epidemiology, classification, risk factors, diagnostic and prognostic markers, and current treatment strategies","volume":"26","author":"Forma A","year":"2025","unstructured":"Forma A, K\u0142odnicka K, Paj\u0105k W, Flieger J, Teresi\u0144ska B, Januszewski J, Baj J. Thyroid cancer: epidemiology, classification, risk factors, diagnostic and prognostic markers, and current treatment strategies. Int J Mol Sci. 2025, 26:5173. 10.3390\/ijms26115173","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00027-9","article-title":"Thyroid cancer incidence trends by histology in 25 countries: a population-based study","volume":"9","author":"Miranda-Filho A","year":"2021","unstructured":"Miranda-Filho A, Lortet-Tieulent J, Bray F, Cao B, Franceschi S, Vaccarella S, Dal Maso L. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 2021, 9:225-34. 10.1016\/S2213-8587(21)00027-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00223-7","article-title":"Evolving epidemiological patterns of thyroid cancer and estimates of overdiagnosis in 2013-17 in 63 countries worldwide: a population-based study","volume":"12","author":"Li M","year":"2024","unstructured":"Li M, Dal Maso L, Pizzato M, Vaccarella S. Evolving epidemiological patterns of thyroid cancer and estimates of overdiagnosis in 2013-17 in 63 countries worldwide: a population-based study. Lancet Diabetes Endocrinol. 2024, 12:824-36. 10.1016\/S2213-8587(24)00223-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0684","article-title":"Long-term declines of thyroid cancer mortality: an international age-period-cohort analysis","volume":"30","author":"Li M","year":"2020","unstructured":"Li M, Brito JP, Vaccarella S. Long-term declines of thyroid cancer mortality: an international age-period-cohort analysis. Thyroid. 2020, 30:838-46. 10.1089\/thy.2019.0684","journal-title":"Thyroid"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0662","article-title":"Thyroid cancer incidence and mortality trends in the United States: 2000-2018","volume":"32","author":"Megwalu UC","year":"2022","unstructured":"Megwalu UC, Moon PK. Thyroid cancer incidence and mortality trends in the United States: 2000-2018. Thyroid. 2022, 32:560-70. 10.1089\/thy.2021.0662","journal-title":"Thyroid"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-02157-2","article-title":"High aggressiveness of papillary thyroid cancer: from clinical evidence to regulatory cellular networks","volume":"10","author":"Zhang J","year":"2024","unstructured":"Zhang J, Xu S. High aggressiveness of papillary thyroid cancer: from clinical evidence to regulatory cellular networks. Cell Death Discov. 2024, 10:378. 10.1038\/s41420-024-02157-2","journal-title":"Cell Death Discov"},{"key":"ref8","unstructured":"SEER*Explorer. An interactive website for SEER cancer statistics. (2025). Accessed: August 05, 2025: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=650&data_type=4&graph_type=5&compareBy=stag...."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061405","article-title":"PD-1 ligand expression in epithelial thyroid cancers: potential clinical implications","volume":"20","author":"Ulisse S","year":"2019","unstructured":"Ulisse S, Tuccilli C, Sorrenti S, et al.. PD-1 ligand expression in epithelial thyroid cancers: potential clinical implications. Int J Mol Sci. 2019, 20:1405. 10.3390\/ijms20061405","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050794","article-title":"Thyroid cancer-the tumor immune microenvironment (TIME) over time and space","volume":"17","author":"Jaume JC","year":"2025","unstructured":"Jaume JC. Thyroid cancer-the tumor immune microenvironment (TIME) over time and space. Cancers (Basel). 2025, 17:794. 10.3390\/cancers17050794","journal-title":"Cancers (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/S42047-024-00157-1","article-title":"Predictive biomarkers in thyroid cancer in the current molecular-morphology paradigm","volume":"7","author":"Carvalho Carneiro H","year":"2024","unstructured":"Carvalho Carneiro H, De Andrade Natal R, Farias EC, et al.. Predictive biomarkers in thyroid cancer in the current molecular-morphology paradigm. Surg Exp Pathol. 2024, 7:1-14. 10.1186\/S42047-024-00157-1","journal-title":"Surg Exp Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025315","article-title":"Association between programmed cell death ligand 1 expression and thyroid cancer: a meta-analysis","volume":"100","author":"Wan B","year":"2021","unstructured":"Wan B, Deng P, Dai W, et al.. Association between programmed cell death ligand 1 expression and thyroid cancer: a meta-analysis. Medicine (Baltimore). 2021, 100:e25315. 10.1097\/MD.0000000000025315","journal-title":"Medicine (Baltimore)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0441","article-title":"Clinicopathologic and prognostic significance of programmed cell death ligand 1 expression in patients with non-medullary thyroid cancer: a systematic review and meta-analysis","volume":"28","author":"Aghajani M","year":"2018","unstructured":"Aghajani M, Graham S, McCafferty C, et al.. Clinicopathologic and prognostic significance of programmed cell death ligand 1 expression in patients with non-medullary thyroid cancer: a systematic review and meta-analysis. Thyroid. 2018, 28:349-61. 10.1089\/thy.2017.0441","journal-title":"Thyroid"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-020-09630-5","article-title":"Programmed death-ligand 1 (PD-L1) is a potential biomarker of disease-free survival in papillary thyroid carcinoma: a systematic review and meta-analysis of PD-L1 immunoexpression in follicular epithelial derived thyroid carcinoma","volume":"31","author":"Girolami I","year":"2020","unstructured":"Girolami I, Pantanowitz L, Mete O, et al.. Programmed death-ligand 1 (PD-L1) is a potential biomarker of disease-free survival in papillary thyroid carcinoma: a systematic review and meta-analysis of PD-L1 immunoexpression in follicular epithelial derived thyroid carcinoma. Endocr Pathol. 2020, 31:291-300. 10.1007\/s12022-020-09630-5","journal-title":"Endocr Pathol"},{"key":"ref15","article-title":"AJCC Cancer Staging Manual","author":"Amin MB","year":"2017","unstructured":"Amin MB, Edge SB, Greene FL, et al.. AJCC Cancer Staging Manual. Springer, New York; 2017."},{"key":"ref16","unstructured":"Agilent Technologies Inc. PD-L1 IHC 22C3 pharmDx Rx only code SK006 50 tests for use with Autostainer Link 48. (2025). Accessed: August 05, 2025: https:\/\/www.agilent.com\/cs\/library\/packageinsert\/public\/P03951E_20.pdf."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03726-1","article-title":"The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis","volume":"73","author":"Li JB","year":"2024","unstructured":"Li JB, Lai MY, Lin ZC, et al.. The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis. Cancer Immunol Immunother. 2024, 73:132. 10.1007\/s00262-024-03726-1","journal-title":"Cancer Immunol Immunother"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen BR","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, et al.. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016, 26:1-133. 10.1089\/thy.2015.0020","journal-title":"Thyroid"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0421","article-title":"Comprehensive screening for PD-L1 expression in thyroid cancer","volume":"24","author":"Ahn S","year":"2017","unstructured":"Ahn S, Kim TH, Kim SW, et al.. Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer. 2017, 24:97-106. 10.1530\/ERC-16-0421","journal-title":"Endocr Relat Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2017.04.033","article-title":"Predictive relevance of programmed cell death protein 1 and tumor-infiltrating lymphocyte expression in papillary thyroid cancer","volume":"163","author":"Aghajani MJ","year":"2018","unstructured":"Aghajani MJ, Yang T, McCafferty CE, Graham S, Wu X, Niles N. Predictive relevance of programmed cell death protein 1 and tumor-infiltrating lymphocyte expression in papillary thyroid cancer. Surgery. 2018, 163:130-6. 10.1016\/j.surg.2017.04.033","journal-title":"Surgery"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-018-2357-6","article-title":"In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related","volume":"472","author":"Bai Y","year":"2018","unstructured":"Bai Y, Guo T, Huang X, et al.. In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related. Virchows Arch. 2018, 472:779-87. 10.1007\/s00428-018-2357-6","journal-title":"Virchows Arch"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-017-0662-z","article-title":"PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma","volume":"12","author":"Bai Y","year":"2017","unstructured":"Bai Y, Niu D, Huang X, et al.. PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma. Diagn Pathol. 2017, 12:72. 10.1186\/s13000-017-0662-z","journal-title":"Diagn Pathol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0228","article-title":"Programmed death-ligand 1 expression in papillary thyroid cancer and its correlation with clinicopathologic factors and recurrence","volume":"27","author":"Shi RL","year":"2017","unstructured":"Shi RL, Qu N, Luo TX, et al.. Programmed death-ligand 1 expression in papillary thyroid cancer and its correlation with clinicopathologic factors and recurrence. Thyroid. 2017, 27:537-45. 10.1089\/thy.2016.0228","journal-title":"Thyroid"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.21203\/RS.3.RS-6175152\/V1","article-title":"Prognostic characterization of papillary thyroid carcinoma: insights into the role of PD-L1 and mutational landscape in disease aggressiveness and outcome","author":"Rana C","year":"2025","unstructured":"Rana C, Mishra P, Makkar I, et al.. Prognostic characterization of papillary thyroid carcinoma: insights into the role of PD-L1 and mutational landscape in disease aggressiveness and outcome. Research Square. 2025, 10.21203\/RS.3.RS-6175152\/V1","journal-title":"Research Square"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8698","article-title":"Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants","volume":"7","author":"Chowdhury S","year":"2016","unstructured":"Chowdhury S, Veyhl J, Jessa F, et al.. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget. 2016, 7:32318-28. 10.18632\/oncotarget.8698","journal-title":"Oncotarget"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030555","article-title":"PD-L1 is an independent prognostic marker in Middle Eastern PTC and its expression is upregulated by BRAFV600E mutation","volume":"13","author":"Siraj AK","year":"2021","unstructured":"Siraj AK, Parvathareddy SK, Pratheeshkumar P, Divya SP, Al-Sobhi SS, Al-Dayel F, Al-Kuraya KS. PD-L1 is an independent prognostic marker in Middle Eastern PTC and its expression is upregulated by BRAFV600E mutation. Cancers (Basel). 2021, 13:555. 10.3390\/cancers13030555","journal-title":"Cancers (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2019.11.007","article-title":"PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study","volume":"52","author":"Fadia M","year":"2020","unstructured":"Fadia M, Fookeerah P, Ali S, Shadbolt B, Greenaway T, Perampalam S. PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study. Pathology. 2020, 52:318-22. 10.1016\/j.pathol.2019.11.007","journal-title":"Pathology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-018-9540-9","article-title":"Papillary thyroid carcinoma emerging from Hashimoto thyroiditis demonstrates increased PD-L1 expression, which persists with metastasis","volume":"29","author":"Lubin D","year":"2018","unstructured":"Lubin D, Baraban E, Lisby A, Jalali-Farahani S, Zhang P, Livolsi V. Papillary thyroid carcinoma emerging from Hashimoto thyroiditis demonstrates increased PD-L1 expression, which persists with metastasis. Endocr Pathol. 2018, 29:317-23. 10.1007\/s12022-018-9540-9","journal-title":"Endocr Pathol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2018-0342","article-title":"Programmed cell death-ligand 1 overexpression in thyroid cancer","volume":"25","author":"Zhang GQ","year":"2019","unstructured":"Zhang GQ, Wei WJ, Song HJ, et al.. Programmed cell death-ligand 1 overexpression in thyroid cancer. Endocr Pract. 2019, 25:279-86. 10.4158\/EP-2018-0342","journal-title":"Endocr Pract"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-12-0313","article-title":"Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation","volume":"20","author":"Cunha LL","year":"2013","unstructured":"Cunha LL, Marcello MA, Morari EC, et al.. Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation. Endocr Relat Cancer. 2013, 20:103-10. 10.1530\/ERC-12-0313","journal-title":"Endocr Relat Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/398114-prognostic-value-of-programmed-cell-death-ligand-1-pd-l1-expression-in-patients-with-papillary-thyroid-carcinoma-a-retrospective-biomarker-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T11:32:56Z","timestamp":1756553576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/398114-prognostic-value-of-programmed-cell-death-ligand-1-pd-l1-expression-in-patients-with-papillary-thyroid-carcinoma-a-retrospective-biomarker-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.91281","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,30]]}}}